Assessment of Serum Leptin in Vitiligo Patients

Not Applicable

Not yet recruiting

• Conditions: Vitiligo
• Interventions: Diagnostic Test: serum leptin

• Registration Number: NCT05549869
• Lead Sponsor: Sohag University

Brief Summary

Evaluation of serum leptin in vitiligo patients and control Assessing its correlation to the body mass index and disease dermographic data .

Detailed Description

, leptin is supposed to contribute to vitiligo pathogenesis through promoting the release of pro-inflammatory mediators such as tumor necrosis factor α "TNF," IL-2 and IL-6, as well as enhancing cytotoxic T cells "CD8" recruitment and inhibiting the functions of regulatory T cells "Tregs". Leptin can also aid in induction of oxidative stress by activating nicotinamide adenine dinucleotide phosphate (NADPH) oxidase• Venous blood samples will be taken from patients and controls to evaluate serum leptin: Morning samples will be taken after 12-h overnight fast in plain vacutainer tubes and directly centrifuged (1098 g for 15 min).

* Sera will be then collected in plain, capped, 5 ml centrifuge tubes "Eppendorf" and freezed at -20ᵒC in a well-monitored freezer until the analysis is performed• Serum leptin will be quantitatively assessed in vitro using DRG leptin Sandwich Enzyme Linked Immuno-Sorbent Assay "ELISA".

* ELISA will be performed according to manufacturer's guidelines where each run included a standard curve.

* Using the mean absorbance value for each sample, the corresponding concentration from the standard curve will be determined.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Status Verified: 2022-09
• Study First Submitted: 2022-09-18
• Study First Submitted QC: 2022-09-18
• Last Update Submitted: 2022-09-18
• Study First Posted: 2022-09-22
• Last Update Posted: 2022-09-22
• Study Start: 2022-11
• Primary Completion: 2023-09
• Study Completion: 2023-09

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 400

Inclusion Criteria

• All patients with vitiligo who are above the age of 18 years

Read More

Exclusion Criteria

• Patients with other autoimmune diseases

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
group A	serum leptin	obese with vitligo
group b	serum leptin	obese without vitligo
group D	serum leptin	non obese without vitiligo
group C	serum leptin	non obese with vitiligo

Primary Outcome Measures

Name	Time	Method
level of serum leptin	6 month	Evaluation of serum leptin in vitiligo patients and control Assessing its correlation to the body mass index and disease dermographic data .

Trial Locations

Locations (1)

Sohag University Hospital; 🇪🇬 Sohag, Egypt